Massive Bio Newsletter June'25

This month, we reflect on our impactful presence at ASCO 2025, from presenting industry-leading research to earning major recognitions, and continue our engagement with oncology stakeholders across Europe. Dive in for concise updates on scientific contributions, awards, and global fieldwork.

Highlights from this edition,

• ASCO 2025: Presentations, booth activity, and recognitions

• Featured by Caplin News at ASCO

• Women in AI USA Award: Selin Kurnaz recognized as AI Innovator of the Year

• CB Insights recognition for AI Drug Development

Selin Kurnaz Named AI Innovator of the Year

Massive Bio's Co-founder and CEO, Selin Kurnaz, received the Women in AI USA 2025 Award for AI Innovator of the Year in the private sector. The award honors her leadership in applying AI to transform clinical trial access, breaking down systemic barriers, and delivering smarter, more equitable solutions for cancer patients worldwide.

ASCO 2025 Highlights

At the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, our team presented the largest prospective study on AI-driven trial matching, shared our pre-screening platform in a joint ASCO/ESMO session, and engaged in hundreds of strategic discussions. Selin Kurnaz was named a PCC Wayfinder for her leadership in data-driven access, and we held live platform demos at Booth IH04. To see our full scientific contributions and key achievements from ASCO 2025, view our summary PDF here.

CB Insights Recognition

Massive Bio was featured in two categories on CB Insights’ AI Drug R&D Market Map: Clinical Trial Matching and Patient Recruitment. This underscores our leadership in AI-driven trial matching and patient enrollment, and our growing impact across the pharma value chain.

Caplin News Feature

Dr. Arturo LoAIza-Bonilla MD and Toygun Onaran were featured in Caplin News, where they shared insights on access, data equity, and the importance of cross-sector collaboration in advancing oncology. Their interview highlighted Massive Bio’s mission to bring smarter, tech-enabled solutions to patients and providers worldwide.

Italy – Clinical Engagements in Campobasso and EHA 2025

Stefano Ronchetti, our Account Manager for Italy, represented Massive Bio at an event hosted by Responsible Research Hospital in Campobasso, where he presented our mission and AI-powered solutions to healthcare professionals. The visit served as a meaningful exchange of ideas focused on streamlining clinical trial access and improving workflows.

Additionally, Mert Sari, Director of OUS Provider Engagement, and Stefano held meetings with institutions in Milan, Alessandria, and Vercelli as part of EHA 2025 outreach, supporting hematology trial expansion and introducing the Clinical Network platform to key opinion leaders.

 Spain – Participation in the 12th SAOM Congress

Gisela Saladino, Account Manager for Spain, represented Massive Bio at the 12th SAOM Congress held in Jerez de la Frontera. The event gathered oncology professionals to discuss clinical practice innovation, research collaboration, and patient support. Massive Bio’s presence supported ongoing efforts to strengthen regional ties and drive awareness around clinical trial access.

Poland – Field Engagements Across Poland

Dawid Kriger, Account Manager for Poland, and Tuna Aydin, Director of OUS Provider Engagement, visited Gdańsk, Sopot, and Gdynia from June 16–18 as part of our Clinical Network expansion, strengthening local partnerships and introducing AI-powered trial matching tools. Dawid also represented Massive Bio at the European Cancer Mission Fair in Warsaw, joining discussions on AI in cancer research and equitable trial access in Europe.

Looking Ahead

From ASCO’s global stage to local field visits across Europe, June has been a powerful reminder of how collaboration and technology are transforming clinical research. We’re grateful for your continued support as we work to make clinical trials more accessible, data-driven, and patient-centered. See you next month with more updates from across the Massive Bio network.